Literature DB >> 3662284

Idiopathic nephrotic syndrome. Puncturing the biopsy myth.

A S Levey1, J Lau, S G Pauker, J P Kassirer.   

Abstract

We used decision analysis to compare the conventional strategy of biopsy-tailored therapy with alternative strategies not using renal biopsy in treating adults with idiopathic nephrotic syndrome. We evaluated data on steroid and platelet-inhibitor therapies and a new clinical strategy, empiric sequential therapy. This sequential approach involves use of short-term alternate-day steroid agents, followed by long-term platelet inhibitors for persistent nephrotic syndrome. Our results indicate that, contrary to usual practice, use of renal biopsy is not necessary in caring for adult patients with idiopathic nephrotic syndrome; empiric short-term alternate-day steroid therapy is equally efficacious. If the benefits of platelet-inhibitor therapy for treating membranoproliferative glomerulonephritis are confirmed, empiric sequential therapy also will be equally efficacious. Our study shows how decision analysis can be used to identify superfluous diagnostic procedures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662284     DOI: 10.7326/0003-4819-107-5-697

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  The characteristics of relapse in adult-onset minimal-change nephrotic syndrome.

Authors:  Takashi Takei; Minako Koike; Koichi Suzuki; Satsuki Shirota; Mitsuyo Itabashi; Shigeru Ohtsubo; Hidekazu Sugiura; Keiko Suzuki; Chiari Kojima; Masaki Takahashi; Jun Ino; Tetsuya Ogawa; Keiko Uchida; Ken Tsuchiya; Wako Yumura; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

2.  Deciding on decision analysis.

Authors:  R J Hogg
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

3.  Applying decision analysis to management of adolescent idiopathic nephrotic syndrome.

Authors:  M M Moxey-Mims; F B Stapleton; L G Feld
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.